Trial Profile
A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs R-troloxamide-quinone (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors BioElectronics Corporation; Edison Pharmaceuticals; PTC Therapeutics
- 24 Sep 2018 According to a BioElectronics Corporation Media Release, Robert Miller, was a study principal investigator. The results of this study have been accepted for poster presentation at the International Symposium on ALS and Motor Neuron Disease in Scotland in December, 2018.
- 24 Sep 2018 Results published in the BioElectronics Corporation Media Release
- 23 Jul 2018 Status changed from recruiting to completed.